



Helping to Bring Hematologic Oncology Therapies to Cancer Patients

Clinical trials in hematologic malignancies are complex, more so than in solid tumors, and thus require a higher level of expertise in your CRO partner. Bringing effective heme/ondc therapies from proof-of-concept to market as fast as possible is Worldwide Oncology's mission because every second counts for patients and their families living with blood cancer.



Active Portfolio in a range of heme/ondc trials

Leukemias

- AML, CLL/SLL, CML

Lymphomas

- DLBCL, FL, MCL, NHL, PTCL

Multiple Myeloma

Myelodysplastic Syndrome

Rare Indications

- AITL, PTCL, MZL



We Understand the nuances of heme/ondc trials

- Complex endpoints (Cheson, Lugano, and IMWG)
- Patients with significant comorbidities
- I/E criteria, wash-out windows, rescue medications
- Competitive clinical trial landscape
- Challenging enrollment rates

Exclusively Biopharma-Focused

Built to work exclusively with biopharma, our flexible processes and approach allow us to listen first, align goals, and execute with an eye to rapid shifts when protocols amend or breakthrough designations move a product straight from Phase I to registration.

Seasoned Oncology Experts

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, and Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

A Transparent, People-First Culture

We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention provide program continuity, increased efficiency, and happy investigative sites.

Additional Differentiators



Flexible solutions & best-in-class technologies



Data-centric approach with visual analytics & clinical science



Worldwide Oncology Site Network




Global Footprint: 4,400+ across U.S., E.U., LATAM & APAC

Active Next-Gen Oncology Experience


Working across all phases of clinical development and a range of both solid and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.

Phase




■ Early Phase ■ Late Phase
■ Observational/LTFU

Indication



■ Solid ■ Heme

Drug Class



■ Targeted Therapy ■ Other
■ Immuno-Oncology

About Worldwide Clinical Trials

Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 professionals operating across more than 60 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase – from early-stage and first-in-human studies through Phase III registration trials.

The company's flexible service model – spanning full-service trial management to functional service partnerships through Worldwide Flex – is powered by a people first, partnership driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research.

Learn more at www.worldwide.com



Worldwide
Clinical Trials